Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio, Inc. reported that an entity associated with major holder Edward T. Mathers bought additional securities. On March 10, 2026, New Enterprise Associates 17, L.P., for which Mathers is an affiliated manager, acquired 242,945 Pre-Funded Warrants at $11.109 per underlying share and 207,100 shares of Common Stock at $11.110 per share in a purchase coded as an open-market transaction and documented in a Subscription Agreement dated March 9, 2026.
The Pre-Funded Warrants are immediately exercisable at an exercise price of $0.001 per share but contain a Beneficial Ownership Limitation that generally caps the holder’s ownership at 9.99% of Korro Bio’s outstanding Common Stock after exercise, with the cap adjustable on 61 days’ notice up to 19.99%. Following these transactions, indirect holdings reported for Common Stock totaled 1,297,893 shares.
Korro Bio, Inc. reported insider-related purchases of both common stock and pre-funded warrants by an entity associated with major holder Mohamad Makhzoumi. On March 10, 2026, New Enterprise Associates 17, L.P. acquired 242,945 pre-funded warrants at $11.1090 per underlying share and 207,100 shares of common stock at $11.1100 per share in open-market or private transactions pursuant to a Subscription Agreement dated March 9, 2026. The pre-funded warrants are exercisable at $0.0010 per share and include a beneficial ownership cap of 9.99%, which the holder may adjust to as high as 19.99% with 61 days’ prior notice.
Korro Bio, Inc. insider Paul Edward Walker, a reported ten percent owner through New Enterprise Associates entities, reported net purchases of Korro Bio securities. An affiliate bought 242,945 Pre-Funded Warrants, each exercisable into one share of Common Stock at an exercise price of $0.001 per share, at a purchase price of $11.109 per warrant.
The same affiliated fund also bought 207,100 shares of Common Stock at $11.11 per share, bringing its indirect Common Stock holdings to 1,297,893 shares following the transactions. All securities are held indirectly by New Enterprise Associates 17, L.P., and Walker disclaims beneficial ownership of any portion in which he has no pecuniary interest.
The Pre-Funded Warrants are immediately exercisable but include a beneficial ownership limitation: they cannot be exercised if doing so would cause the holder and certain related parties to exceed 9.99% of Korro Bio’s outstanding Common Stock, a cap that can be adjusted up to 19.99% with 61 days’ prior notice.
Florence Anthony A. Jr. reported open-market purchase transactions in this Form 4 filing.
Korro Bio, Inc. disclosed that investment fund New Enterprise Associates 17, L.P. (NEA 17), an entity associated with 10% owner Anthony A. Florence Jr., entered into a Subscription Agreement with the company. On March 10, 2026, NEA 17 acquired 242,945 Pre-Funded Warrants at $11.109 per underlying share and 207,100 shares of Common Stock at $11.11 per share. Following the transaction, NEA 17 held 242,945 pre-funded warrants (each exercisable into one share of Common Stock at $0.001 per share) and 1,297,893 shares of Common Stock. The pre-funded warrants are exercisable at any time but include a 9.99% beneficial ownership cap, which the holder may adjust upon 61 days' notice, not to exceed 19.99%. Florence is a manager of the NEA 17 general partner and disclaims beneficial ownership of portions of these securities in which he has no pecuniary interest.
New Enterprise Associates 17, L.P. and affiliated entities report a 9.9% beneficial stake in Korro Bio, Inc. common stock. They are deemed to own 1,435,487 shares in total, including 1,297,893 shares of common stock and 137,594 shares issuable from pre-funded warrants and options.
As part of a March 2026 private placement, NEA 17 purchased 207,100 Korro Bio shares at $11.11 per share and pre-funded warrants for 242,945 shares at $11.109 per warrant, with a $0.001 exercise price. The warrants are subject to a Beneficial Ownership Limitation initially set at 9.99%, adjustable up to 19.99% with 61 days’ notice.
Korro Bio, Inc. describes its strategy to develop RNA editing medicines for rare and common diseases using its OPERA platform. The company’s lead candidate, KRRO-121, targets hyperammonemia in urea cycle disorders and hepatic encephalopathy, with a first-in-human enabling filing anticipated in the second half of 2026.
Korro is also advancing a next‑generation GalNAc‑conjugated program for alpha‑1 antitrypsin deficiency with development candidate nomination expected in the second quarter of 2026. Additional longevity, liver health and ALS programs, together with a paused Novo Nordisk collaboration, are supported by a cash runway into the second half of 2028.
Korro Bio reported full-year 2025 results showing progress in its RNA-editing pipeline alongside higher losses. Collaboration revenue rose to $6.4 million from $2.3 million in 2024, while research and development expenses grew slightly to $65.6 million and general and administrative costs declined to $28.2 million.
The company recorded $30.9 million of non-cash long-lived asset impairment charges and $3.6 million in restructuring charges tied to 2025 workforce reductions, driving net loss to $117.3 million versus $83.6 million in 2024. Cash, cash equivalents and marketable securities were $85.2 million as of December 31, 2025, and an oversubscribed $85 million private placement completed in March 2026 is expected to fund operations into the second half of 2028.
Operationally, Korro nominated KRRO-121 as a development candidate for hyperammonemia in urea cycle disorders and hepatic encephalopathy, advanced its GalNAc-conjugated alpha-1 antitrypsin deficiency program with plans to nominate a candidate in the second quarter of 2026, and continued preclinical work in longevity, liver health, and ALS.
Korro Bio, Inc. Schedule 13G: Point72 group reports beneficial ownership of 816,885 shares (5.7%) as of March 10, 2026.
The filing lists shared voting and dispositive power across affiliated entities and individuals, with holdings shown by reporting persons including Point72 Asset Management (540,054 shares) and Point72 Biotech Private Investments, LLC (276,831 shares). The reporting persons filed jointly under a Joint Filing Agreement.
Korro Bio, Inc. entered into a subscription agreement for an oversubscribed private placement expected to deliver approximately $85.0 million in gross proceeds. The company will sell 4,501,928 shares of common stock at $11.11 per share and pre-funded warrants to purchase 3,148,836 shares at $11.109 per warrant, with a $0.001 exercise price.
The financing, led by Venrock Healthcare Capital Partners with multiple new and existing institutional investors, together with Korro’s preliminary unaudited $85.2 million in cash, cash equivalents and marketable securities as of December 31, 2025, is expected to extend the company’s cash runway into the second half of 2028. Proceeds are intended to advance Korro’s RNA editing pipeline, including clinical data for KRRO-121 in urea cycle disorders, its GalNAc-conjugated alpha-1 antitrypsin deficiency program, and a longevity and liver health program targeting the AMPKγ1 pathway, with the balance for working capital and general corporate purposes.
Point72-affiliated entities filed an amended Schedule 13G reporting a 2.9% passive stake in Korro Bio, Inc. common stock. As of the close of business on December 31, 2025, Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, 72 Investment Holdings, LLC and Steven A. Cohen are each reported as beneficial owners of 276,831 shares of Korro Bio common stock, representing 2.9% of the outstanding class. Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. report no direct holdings, though the filing describes their roles in managing and controlling affiliated entities. The signatories certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Korro Bio.